

Reference:	FOI.5160.21
Subject:	Biologic drugs
Date of Request:	28 January 2021

Requested:

1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
 - Adalimumab - Humira
 - Adalimumab Biosimilar
 - Apremilast
 - Brodalumab
 - Certolizumab
 - Dimethyl fumarate
 - Etanercept - Enbrel
 - Etanercept Biosimilar
 - Guselkumab
 - Infliximab - Remicade
 - Infliximab Biosimilar
 - Ixekizumab
 - Risankizumab
 - Secukinumab
 - Tildrakizumab
 - Ustekinumab

2. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
 - Adalimumab – Humira
 - Adalimumab Biosimilar
 - Golimumab
 - Infliximab – Remicade
 - Infliximab Biosimilar
 - Tofacitinib
 - Ustekinumab
 - Vedolizumab

3. If possible, could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department for Ulcerative Colitis ONLY with the following biologic drugs:
 - Adalimumab – Humira
 - Adalimumab Biosimilar
 - Golimumab
 - Infliximab – Remicade

- Infliximab Biosimilar
- Tofacitinib
- Ustekinumab
- Vedolizumab

Response:

Hywel Dda University Health Board is unable to provide you with the information requested as it is estimated that the cost of answering your request would exceed the “appropriate level” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004.

The “appropriate level” represents the estimated cost of one person spending 18 hours or (2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the number of patients that were prescribed the listed medications, the UHB would need to cross reference the dispensed medications with the patient records to identify the information requested.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000, which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the *appropriate limit*.

Under section 16 of the Freedom of Information Act 2000, the UHB has an obligation to provide advice and assistance. The UHB has therefore provided the number of medications dispensed for questions 1 and 2.

1. The UHB provides, within the table below, the number of medications dispensed by the Dermatology department, during the period 1 November 2020 to 31 January 2021.

Medication	Number dispensed
Adalimumab – Humira	2
Adalimumab Biosimilar	66
Apremilast	20
Brodalumab	0
Certolizumab	0
Dimethyl fumarate	3
Etanercept – Enbrel	0
Etanercept Biosimilar	6
Guselkumab	0
Infliximab – Remicade	0
Infliximab Biosimilar	0
Ixekizumab	3
Risankizumab	0
Secukinumab	29
Tildrakizumab	0
Ustekinumab	37

2. The UHB provides, within the table below, the number of medications dispensed by the Gastroenterology department, during the period 1 November 2020 to 31 January 2021.

Medication	Number dispensed
Adalimumab – Humira	18
Adalimumab Biosimilar	61
Golimumab	0
Infliximab – Remicade	2
Infliximab Biosimilar	19
Tofacitinib	0
Ustekinumab	20
Vedolizumab	29